BCL2 and neoplasm: Bcl‐2 was previously shown to be overexpressed in ∼85% of ER+ breast malignancies, and Bcl‐2 positivity has been associated with poor clinical outcome in TNBC models, suggesting possible therapeutic vulnerabilities within both luminal and basal subtyped tumours.72, 73